Jonathan Jay Mazelsky - 13 Feb 2025 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Role: President and CEO, Director
Signature: /s/ Lily J. Lu, Attorney-in-Fact for Jonathan Jay Mazelsky
Issuer symbol: IDXX
Transactions as of: 13 Feb 2025
Net transactions value: -$543,216
Form type: 4
Filing time: 18 Feb 2025, 21:43:38 UTC
Previous filing: 14 Jan 2025
Next filing: 02 Apr 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IDXX	Common Stock	Options Exercise	$0	+689	+0.84%	$0.000000	82,447	14 Feb 2025	Direct	F1
transaction	IDXX	Common Stock	Options Exercise	$0	+958	+1.2%	$0.000000	83,405	14 Feb 2025	Direct
transaction	IDXX	Common Stock	Options Exercise	$0	+1,100	+1.3%	$0.000000	84,505	14 Feb 2025	Direct
transaction	IDXX	Common Stock	Tax liability	$543,216	-1,222	-1.4%	$444.53	83,283	14 Feb 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IDXX	Non-Qualified Stock Option (right-to-buy)	Award	$0	+25,932		$0.000000	25,932	13 Feb 2025	Common Stock	25,932	$459.76	Direct	F2
transaction	IDXX	Incentive Stock Option (right-to-buy)	Award	$0	+217		$0.000000	217	13 Feb 2025	Common Stock	217	$459.76	Direct	F3
transaction	IDXX	Restricted Stock Unit	Options Exercise	$0	-689	-100%	$0.000000	0	14 Feb 2025	Common Stock	689		Direct	F4
transaction	IDXX	Restricted Stock Unit	Options Exercise	$0	-958	-50%	$0.000000	958	14 Feb 2025	Common Stock	958		Direct	F5
transaction	IDXX	Restricted Stock Unit	Options Exercise	$0	-1,100	-33%	$0.000000	2,198	14 Feb 2025	Common Stock	1,100		Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes a total of 25 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2024 and December 31, 2024
F2	Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2026.
F3	Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2029.
F4	Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2022.
F5	Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2023.
F6	Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024.